Edgewise shares slide amid trial and stock news

3 April 2025

Colorado, USA-based Edgewise Therapeutics (Nasdaq: EWTX), a muscle disease-focused biopharma company, closed 23% lower after Wednesday’s trading.

Edgewise earlier revealed new Phase II results on its cardiac drug EDG-7500 in hypertrophic cardiomyopathy (HCM) as well as announcing the pricing of $200 million underwritten offering of common stock.

Although the four-week data presented from parts B and C of the CIRRUS-HCM trial showed promising efficacy across measures of feel and function, reductions in key cardiac biomarkers and positive trends in measures of diastolic function, two patients experienced serious adverse events of atrial fibrillation requiring cardioversion. This issue was of likely concern to investors as Edgewise moves towards a Phase III trial of EDG-7500.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK